BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
土曜日, 9 26

Structure Therapeutics Inc

GPCRNASDAQ
Trade with Public
Trade with Public
$35.93
-0.09-0.25%
近くで: Sep 25, 5:00 PM EST
$35.96
0.030.08%
時間外: 4:00 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Structure Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Structure Therapeutics (GPCR).

Price Target Range — 13 Quarters

Analyst Consensus — 16 Analysts

3S.Buy
13Buy
Consensus RatingBuy# Analysts16Avg. Consensus PT$98Upside to Avg. PT+172.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Sep 9, 2026CitizensJonathan WollebenMaintainedMarket Outperform$110
Aug 7, 2026CitigroupSamantha SemenkowPT CutBuy$100→$97
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on Structure Therapeutics, Maintains $110 Price Target

Citizens analyst Jonathan Wolleben reiterates Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and maintains $110 price target.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97

Citigroup analyst Samantha Semenkow maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $100 to $97.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110

Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and lowers the price target from $113 to $110.
Benzinga Newsdesk

Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ratings page: CHEF, NAVN, INTC, HOOD, GPCR, OTLK, ORCL.
Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70

HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $100 to $70.
Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On Structure Therapeutics with Buy Rating, Announces Price Target of $101

Canaccord Genuity analyst Edward Nash initiates coverage on Structure Therapeutics (NASDAQ:GPCR) with a Buy rating and announces Price Target of $101.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved